Methamphetamine: Difference between revisions
From Pharmacopedia
More actions
| [checked revision] | [pending revision] |
MDElliottMD (talk | contribs) No edit summary |
MDElliottMD (talk | contribs) Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved. |
||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 15: | Line 15: | ||
| pregnancy = Category C (per Desoxyn label) | | pregnancy = Category C (per Desoxyn label) | ||
| legal = Schedule II | | legal = Schedule II | ||
| mechanism = Monoamine releasing agent | | mechanism = Monoamine releasing agent, TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport | ||
| intro = '''Methamphetamine''' is a CNS stimulant of the amphetamine class. It is FDA-approved (as '''Desoxyn''') for attention-deficit hyperactivity disorder and short-term management of obesity. It is a Schedule II controlled substance in the United States. | | intro = '''Methamphetamine''' is a CNS stimulant of the amphetamine class. It is FDA-approved (as '''Desoxyn''') for attention-deficit hyperactivity disorder and short-term management of obesity. It is a Schedule II controlled substance in the United States. | ||
| indications = < | | indications = <problem slug="adhd" title="ADHD in children, adolescents, and adults" author="MDElliottMD"/> | ||
< | <problem slug="obesity" title="Obesity (short-term)" author="MDElliottMD"/> | ||
| dosing = | effects = | | dosing = | effects = | ||
* <effect ref="attention" author="MDElliottMD"/> | * <effect ref="attention" author="MDElliottMD"/> | ||
| Line 50: | Line 50: | ||
| pk_elimination = Urinary elimination is pH-dependent. | | pk_elimination = Urinary elimination is pH-dependent. | ||
| pharmacodynamics = Methamphetamine acts at monoaminergic terminals as a releasing agent via TAAR1 agonism, VMAT2 substrate activity, and DAT/NET reverse transport. Secondary mechanisms include weak monoamine reuptake inhibition. | | pharmacodynamics = Methamphetamine acts at monoaminergic terminals as a releasing agent via TAAR1 agonism, VMAT2 substrate activity, and DAT/NET reverse transport. Secondary mechanisms include weak monoamine reuptake inhibition. | ||
| interactions = * '''MAOIs''', contraindicated (per label) | |||
* '''Acidifying agents''', increase urinary clearance | |||
* '''Alkalinizing agents''', decrease urinary clearance | |||
<pharmaInteractions/> | |||
| interactions = * '''MAOIs''' | |||
* '''Acidifying agents''' | |||
* '''Alkalinizing agents''' | |||
| pregnancy_details = Category C per Desoxyn label. | | pregnancy_details = Category C per Desoxyn label. | ||
| monitoring = | | monitoring = | ||
| Line 71: | Line 62: | ||
}} | }} | ||
[[Category:Psychostimulants]] | |||
[[Category:Amphetamines]] | |||
[[Category:Psychostimulants]] | [[Category:Psychostimulants]] | ||
[[Category:Phenethylamines]] | |||